Please login to the form below

Not currently logged in


This page shows the latest PRINCIPLE study news and features for those working in and with pharma, biotech and healthcare.

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients

Results from this study showed that 11.2% of hospitalised COVID-19 patients who received Farxiga experienced an organ failure or died after 30 days of treatment versus 13.8% in ... reasonable doubt because patient outcomes rapidly improved during the

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...